An interventional study of RIRS using the TaloStone T1000 RIRS platform in Renal Stone, sponsored by Chinese University of Hong Kong. Recruiting at 2 sites in Hong Kong. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment
This is a phase I feasibility study to investigate the use of a novel intelligent robotic retrograde intrarenal surgery (RIRS) platform. The TaloStone T1000 RIRS system can manipulate the flexible ureteroscope, with remote control of the instruments (laser fibre or basket) and ureteral access sheath movements. Beyond teleoperation, the TaloStone T1000 RIRS system integrates AI perception models and decision-making algorithms to enable the supervised autonomous execution of critical tasks within the RIRS workflow.
I. Introduction
Retrograde intrarenal surgery (RIRS) has become a preferred method for the diagnosis and treatment of urological diseases, such as kidney stone removal. However, the complex urinary and limited visibility of existing endoscope lead to inefficient manipulation of flexible ureteroscopes. Besides, conventional flexible ureteroscopy requires repetitive manual manipulation, which often results in surgeon fatigue, mucosa injury from respiratory motion, and variable stone clearance rates, particularly in complex calyceal anatomies.
The research focuses on the development of an novel robotic system for RIRS, currently dubbed "TaloStone T1000". The robotic system platform consists of a surgeon control console, a multi-functional video cart, and patient-side robotic arm with fiber-optic-sensitized flexible ureteroscopy as shown in Fig. 1. The surgeon console with optimized design of ergonomics is equipped with haptic master devices for smooth and precise control of the robotic arm to manipulate the flexible ureteroscope as well as instruments, e.g., stone baskets and laser fibers. The system also supports seamless integration of multiple modalities, including pre-operative CT scans, intra-operative endoscopic videos, and fiber-optic sensing. Besides, the self-developed flexible ureteroscope is embedded with fiber optic sensors for real-time shape sensing, force estimation, and simultaneous intrarenal pressure control and temperature monitoring. Shape sensing enables precise navigation of the ureteroscope within the renal collecting system, and force estimation provides accurate feedback of tip contact interaction to the master devices on the surgeon control.
Moreover, AI algorithms are incorporated to assist in diagnostics and higher level of supervised surgical autonomy, thereby improving safety and efficiency. The investigators developed AI-powered diagnostics for stone sensing, laser fiber recognition, depth awareness, and CT-to-endoscopy localization. Based on the sensing results from AI-powered diagnostics, the investigators proposed a supervised framework that can automate repetitive procedures throughout in-sheath and ureter navigation, laser approaching, and laser trajectory planning. The entire operation is under supervision of the surgeon, who can use one trigger on the master device or footswitch to enable or disable the supervised automated features. The foot pedal of laser device remains to trigger laser emission by the surgeon for stone fragmentation, dusting, and pop-corning. The basic safety and essential performance of both hardware and software in the robotic system were developed under clinical standards and medical device regulations.
To date, a total of three cadaveric studies have been conducted using the robotic system. In August 2024, the investigators performed the first cadaver study of the robotic system at Prince of Wales Hospital (PWH), where user study of ergonomic manners and tele-operation control of stone treatment was investigated. The second and third cadaver studies, focusing on the AI-powered features of the robotic system, were completed at PWH in June and December 2025. Synthetic renal stones of around 3mm were retrogradely inserted to the renal collecting systems, with successful fragmentation via the robotic RIRS system using Holmium:YAG laser. Over 10 doctors from PWH and the Chinese University of Hong Kong, participated in the cadaver studies. The current system response, motion speed of the robotic system, and operations with ergonomic control console can satisfy the requirements of the doctors. In addition to the cadaver studies, the investigators have conducted a set of laboratory testing and experiments, validating its robustness and stability of the system.
Subsequent to successful cadaveric experiments, the investigators planned to further validate of the feasibility of the use of the system in clinical cases. In this study, the investigators aim to evaluate the robotic system's safety and feasibility in RIRS in a stage 1, proof of concept study that follows the concepts outlined in the IDEAL framework (Idea, Development, Exploration, Assessment, Long-term Study).
II. Methods
Aim
The aim of this study is to evaluate the feasibility and safety of performing RIRS using the TaloStone T1000 system.
Study Design
This is a prospective, single-arm study that will be conducted by investigators from The Chinese University of Hong Kong/Prince of Wales Hospital in the period from November 2025 to June 2026. The investigators are experts in endo-urological surgery and robot-assisted surgery. The study design follows the guidelines for stage 1 of the IDEAL framework. The study will be carried out in accordance with the Declaration of Helsinki of the World Medical Association and the International Conference on Harmonization - Good Clinical Practice.
The study information will be provided to subjects during a preoperative consultation by the investigators and the research staff. Subjects will be provided with approved informed consent explaining the study procedure, risks, assessments, and required compliance; and will be given ample time to make their decision regarding participation in the study.
Perioperative data and outcomes from all cases of those participating in the study will be reviewed by an independent Data and Safety Monitoring Committee (consisting two senior urologists not involved in this study) for safety and identification of serious perioperative complications (within 30 days after the surgery) as interim to safeguard study subjects. The Committee will make periodic recommendations to the study team on whether to continue, modify, or prematurely terminate the study. Any adverse events will also be immediately reported to the Clinical Research Ethics Committee of the hospital.
Reporting of this stage 1 study will follow the IDEAL Reporting Guidelines.
324 studies on the registry are indexed under Nephrolithiasis; 90 are open to participants now.
This study's planned enrollment of 15 is below the median of 92 across 257 interventional studies indexed under Nephrolithiasis.
Browse Nephrolithiasis studies →Chinese University of Hong Kong is the lead sponsor of 1,454 studies on the registry; 474 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use of the TaloStone T1000 RIRS system
Procedure: RIRS using the TaloStone T1000 RIRS platform
Retrograde intrarenal surgery (RIRS) will be performed using the TaloStone T1000 RIRS system. Beyond teleoperation, the TaloStone T1000 RIRS system integrates advanced AI perception models and decision-making algorithms to enable the autonomous execution of critical tasks within the RIRS workflow. The AI-based vision models coupled with sensors in the fURS allow real-time scene understanding, depth perception, stone size estimation, pressure and temperature feedback, and object tracking - thus establishing a robust foundation for higher level of surgical autonomy. Under supervision by the surgeon, the TaloStone T1000 RIRS system can perform supervised navigation into the collecting system, actively track a target stone, dynamically target the laser fibre tip towards a stone, plan the laser fragmentation route, and perform scope withdrawal for stone suction with re-entry.
Success rate
Successful RIRS by the robotic system, i.e. without conversion to conventional manual RIRS
Time frame: Intra-operative
Stone free rate
* by non-contrast computer tomography (NCCT) performed within 1 month of surgery * without residual stone fragments, or residual stone fragments \<2mm
Time frame: Within post-operative 1 month
Operative time
* total operative time (time from start of operation to the end of operation) * console time (from start of control of robotic system to end of control of robotic system) * robotic control time (defined as time spent manipulating the control for navigation) * robotic set-up time (from the moment the robot is pushed into the operating room to the moment the flexible ureteroscope is attached to the robot) * procedure time (total operative time - The robot set-up time) * lasing time
Time frame: Intra-operative
Total laser energy used
Laser energy in terms of kJ
Time frame: Intra-operative
Total radiation dose during operation
Radiation dose based on fluoroscopy readings
Time frame: Intra-operative
Surgeon radiation exposure
\- by radiation dosimeter
Time frame: Intra-operative
Length of hospital stay
\- days of stay as in-patient
Time frame: During admission period (up to 30 days)
Post-operative pain
\- by visual analogue scale, from 0-10 with 10 being the most pain
Time frame: From immediately post-operatively to discharge (day 0 to day 1)
Post-operative complications
By "Clavien-Dindo Classification"
Time frame: Within post-operative 30 days
Surgeon questionnaires
Completed the Subjective Mental Effort Questionnaire (SMEQ) to assess subjective during RIRS surgery.
Time frame: Immediately post-operative, day 0
Surgeon questionnaires
Completed the System Usability Scale (SUS) questionnaire to assess the subjective usability of the robotic system during RIRS surgery. The questionnaire uses a 1-5 scale, where 1 = Strongly disagree and 5 = Strongly agree.
Time frame: Immediately post-operative, day 0
Surgeon questionnaires
Completed the NASA Task Load Index (NASA-TLX) questionnaire to assess subjective mental and physical demand during RIRS surgery. The questionnaire uses a 1-10 scale, where 1 = Very Low and 10 = Very High.
Time frame: Immediately post-operative, day 0
Surgeon questionnaires
Completed the Simulator Sickness Questionnaire (SSQ) to assess the subjective symptoms experienced during or after RIRS surgery. The questionnaire uses a 0-3 scale, where 0 = None, 1 = Slight, 2 = Moderate, 3 = Severe
Time frame: Immediately post-operative, day 0
Surgeon questionnaires
Completed the Likert Scales on Ergonomics and Comfort questionnaire, which assessed the subjective experience of minimal discomfort or fatigue during RIRS surgery. The questionnaire uses a 1-5 scale, where 1 = Strongly disagree and 5 = Strongly agree.
Time frame: Immediately post-operative, day 0
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code will be available.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: It will be available after the publication of the manuscript (latest 31 Dec 2027 by estimation), and will be available for up to 5 years afterwards
Access criteria: IPD will be shared in a de-identified manner for reasonable studies with approved from the relevant institutional review board.
Started Feb 2026 (actual). Primary completion is estimated for Aug 2027, 18 months after the start.
Of 134 non-industry interventional studies with no phase under Nephrolithiasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 18 months is below that.
Counting every sponsor, half of 140 studies reached it within 24 months; a quarter within 12 and three quarters within 38.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2026 → Aug 2027 and completion Mar 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →